Hemorheology in Inflammatory Bowel Disease: A Case-Control Study

Area of Science:

• Hematology
• Gastroenterology
• Vascular Medicine

Background:

• Patients with inflammatory bowel disease (IBD) have a higher risk of venous thromboembolism (VTE).
• Understanding the hemorheological factors contributing to VTE in IBD is crucial for risk stratification and management.

Purpose of the Study:

• To investigate prothrombotic hemorheological alterations in patients with IBD.
• To identify specific hemorheological indicators associated with VTE risk in IBD.

Main Methods:

• A case-control study comparing IBD patients (ulcerative colitis, Crohn's disease) with non-IBD controls.
• Measurement of hemorheological parameters: plasma viscosity (PV), whole blood viscosity (WBV), erythrocyte aggregation (EA), and erythrocyte deformability (ED).
• Statistical analysis using uni- and multivariate tests, adjusting for inflammatory markers and disease activity.

Main Results:

• IBD patients exhibited significantly enhanced erythrocyte aggregation (EA) compared to controls.
• Fibrinogen was identified as the strongest predictor of enhanced EA, surpassing the Crohn's Disease Activity Index.
• No significant differences in plasma viscosity (PV), whole blood viscosity (WBV), or erythrocyte deformability (ED) were observed between groups after adjusting for covariates.

Conclusions:

• Inflammatory bowel disease is associated with enhanced erythrocyte aggregation, primarily predicted by fibrinogen levels.
• Inflammation is a key driver of the increased venous thromboembolism risk observed in IBD patients.
• These findings underscore the importance of monitoring hemorheological parameters, particularly fibrinogen, in IBD management to mitigate VTE risk.